Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.64
+$0.02 · +0.55%
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Latest quote
$3.64
+$0.02 · +0.55%
After-hours
$3.6389
−$0.0011 · -0.03%
Oct 8, 6:28 PM ET
Regular session · ET · Market data may be delayed.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Day range
Current $3.64
52-week range
Current $3.64
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
52
Mixed
Risk
59
Elevated Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Day range
Current $3.64
52-week range
Current $3.64
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 14.29M USD | 36.57M USD | 32.13M USD | 31.74M USD | 23.82M USD |
| Selling, general, and administrative | 5.8M USD | 5.86M USD | 5.94M USD | 6.62M USD | 6.36M USD |
| Operating expenses | 20.09M USD | 42.43M USD | 38.07M USD | 38.35M USD | 30.18M USD |
| Interest income | 126K USD | 338K USD | 230K USD | 52K USD | 3K USD |
| Interest expense | 7.33M USD | 5.54M USD | 2.79M USD | 1.03M USD | 489K USD |
| Depreciation and amortization | 53K USD | 37K USD | 33K USD | 32K USD | 41K USD |
| Operating income | −20.09M USD | −42.43M USD | −38.07M USD | −38.35M USD | −30.18M USD |
| Net income | −30.84M USD | −47.05M USD | −41.07M USD | −38.78M USD | −30.53M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$11.00
202.20% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 23, 2012 | 1:6 | — | — |
Effective Mar 23, 2012
1:6
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.01M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM4.36M0.01%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF2.46M0.00%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO1.13M0.01%14.25B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO1.09M0.01%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC544.05K0.04%1.33B USD0.60%$182.79-0.31%
Horizon Kinetics Medical ETFMEDX153.68K0.93%16.48M USD0.85%$34.70-0.83%
Vanguard Russell 2000 Growth ETFVTWG141.57K0.01%1.7B USD0.06%$258.14-0.44%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCHorizon Kinetics Medical ETFMEDXVanguard Russell 2000 Growth ETFVTWGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
